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enrolled in this trial. All patients received abciximab before or in the cath-lab before start 
of the PCI. Half of the oatients had orior CPR and 2l3 were intubated on enrolment in the 
study. A 3-vessel disease was present in 72.5% of the patients. An occluded infan vessel 
(TIMI O/l flow) before PCI was obseved in 65%. The oatients were orosoectivelv followed 
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1196-106 Percutaneous Coronary Intervention During the Index 
Hospitalization Is Associated With Reduced Recurrent 
Myocardial Infarction and Improved Survival Following 
Thrombolytic Administration 
C. Michael Gibson, Juhana Karha, Sabina A. Murphy, Christopher P. Cannon, Robert P 
Giugliano. Elliott M. Antman. Eugene Braunwald, The TIMI Study Group, Brigham 8 
Women’s Hospital, Boston, MA 
Background: Recurrent myocardial infarction (reMI). remains a limitation of fibrinolytic 
therapy. We hypothesized that following fibrinolytic administration, performance of percu- 
taneous coronary intervention (PCI) during the index hospitalization is associated with 
lower rates of recurrent MI and death compared to conservative management. Methods: 
Performance of PCI thru hospital discharge and mortality up to 2 years were ascertained 
in the TIMI 4, 9A, 98, 106 and 17 acute Ml trials (n=20,043). Patients whose PCI fol- 
lowed a recurrent Ml (n=266) were included in the medical therapy arm. Results: PCI 
was performed in 21.4% of patients at a median of 4 days (IQ range l-6). In-hospital 
recurrent Ml occurred less frequently in patients treated with PCI vs. patients without PCI 
(1.6% vs. 4.5%, p<O.OOl). Mortality was also lower in patients treated with PCI 
(pc0.0001; Figure). Similar results were seen across the low, intermediate, and high TIMI 
risk scores (Figure). Both PCI and recurrent MI remained associated with 2 year mortality 
in a model adjusting for age, anterior MI. pulse on admission, and gender (PCI hazard 
ratio=0.51, p<O.OOl; recurrent Ml hazard ratio=l.95, p<O.OOl). Conclusion: Following 
thrombolytic administration, PCI during the index hospitalization was associated with a 
lower rate of in-hospital recurrent MI and improved 2 year survival. 
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1196-l 07 Prospective Study of Primary Percutaneous 
Intervention and Abciximab in Patients With ST 
Elevation Myocardial Infarction Complicated by 
Cardiogenic Shock 
Uwe Zevmer, Ulrich Tebbe, Michael W. Weber. Hans-Friedrich Vijhringer, Karl-Ludwig 
Neuhaus. for the ALKK Study Group, Klinikum Ludwigshafen, Ludwigshafen. Germany 
Background: Patients presenting with ST-elevation myocardial imfarction (STEMI) com- 
plicated by cardiogenic shock have a high mortality despite early interventional therapy. 
Antiplatelet therapy with potent GPllb/lllA inhibition with abciximab has been shown to 
reduce ischemic complications after PCI and improve outcome. Therefore we performed 
a prospective multicenter study to evaluate a routine strategy of primary percutaneous 
intervention (PCI) and adjunctive therapy with abciximab in patients with STEMI compli- 
cated by cardiogenic shock. Methods: Fourty patients with STEMI < 12 hrs. were 
. 
for 30-day outcome. Results: The intervention was successfull in 92.5% of the patients, 
60% had TIMI 3 flow after the PCI. A stent was implanted in 65 % of the patients.Major 
bleeding complications were observed in 5% of the patrents. The 30.day mortality rate 
was 42.5%. In patients 575 years (n=29) mortality was 24% whrle all but one (10111) of 
the patients > 75 years died. Conclusion: A routine strategy of primary PCI and adjunc- 
tive therapy with abciximab patients with STEMI complicated by cardiogenic shock is 
safe and associated with a high rate of successful1 interventions and seems to improve 
outcome rn patients 5 75. 
1196-108 Reduction in Hospital Mortality by First Day 
Percutaneous Coronary Intervention for Non-ST 
Elevation Myocardial Infarction in Diabetics: Results of 
the ACOS-Registry 
Anselm K. Gitt Rudolf Schiele, Harm Wienbergen, St&fen Schneider, Tobias Heer, Uwe 
Zeymer, Martin G. Gothvik, Jochen Senges, ACOS-Study-Group. Herzzentrum 
Ludwigshafen, Ludwigshafen, Germany, Klinikum Nuernberg Sued, Nuernberg, 
Germany 
Background: Current studies have reported a reduction in mortality by first day PCI in 
patients (pts) with acute coronary syndromes (ACS) without persistent ST-elevation. 
Data on outcome of high risk diabetics with non-ST-elevation myocardial infarction 
(NSTEMI) in clinical practice do not yet exist. 
Methods: Since June 2000 consecutive pts with ACS have been enrolled into the ACOS- 
Registry in 154 hospitals in Germany. We analysed the impact of first day PCI in diabet- 
ics with NSTEMI on hospital outcome. 
Results: Out of 12154 consecutive patients with ACS, 4954 (41%) presented with 
NSTEMI, of whom 1567 (32%) were diabetics. First day PCI was performed in 31311567 
pts (20%). Determinants in favour of first day PCI were prior PCI / CABG (OR 2.13; 1.56. 
2.61). age < 70 years (OR 1.93; 1.47-2.52) and male gender (OR 1.47; 1 .lO-1.93). A 
determinant against first day PCI in diabetics was prior myocardial infarction (OR 0.51: 
0.35-0.74). 
After adjusting for differences in baseline characteristics and adjunctive therapy, first day 
PCI in diabetics with NSTEMI was associated with a 63% reductron of hospital mortality 
(OR 0.37,o.ia-0.75). 
Conclusion: Determinants for first day PCI in diabetics with NSTEMI were male gender, 
age c 70 years and prior PCI or CABG. First day PCI in acute NSTEMI was associated 
with a high 63% reduction of adjusted odds for hospital mortality. 
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1196-109 Improved Functional Status and Quality of Life After 
Invasive Management of Non-ST-Segment Elevation 
Acute Myocardial Infarction 
Mark J. Eisenberg, Flora F. Teng Muhammad R. Chaudhry Jose Ortiz, Louise Pilate, 
Jewish General Hospital/McGill Universrty, Montreal, PQ, Canada 
Background: While recent studies suggest that clinical outcomes may be improved by 
invasive management following non-ST-segment elevation acute myocardial infarction 
(AMI), it remains unclear whether functional status and quality of life (QOL) are affected 
by an invasive strategy. 
Methods: We randomized 63 patients to invasive vs. non-invasive management foltow- 
ing non-ST-segment elevation AMI. Functional status was assessed using maximal exar- 
cise endurance on a treadmill at 12.months and the Duke Activity Status Index (DASI) at 
both baseline and IP-months. QOL was assessed using the Seattle Angina Question- 
naire (SAQ) and the Medical Outcomes Study 36-Item Short-Form Health Status Survey 
(SF-36) at baseline and 1 P-months. 
Results: Patients were predominantly middle-aged men (56.3 il2.0 years, 61.4% male). 
Of the patients randomized to an invasive strategy, 76.6% received angiography. Of the 
patients randomized to the non-invasive strategy, 91 .I% received functional testing. 
Cumulative revascularization rates were similar in both groups (24.4% vs. 20.0% respec- 
tively). Maximal exercise endurance (set) at 12.months did not show a significant differ- 
ence between the two arms (652.1 vs. 556.7, P=NS). The invasive arm was found to 
have improved functional status by a mean difference of +6.6 (P=O.OZ) in DASI Score 
between IP-months and baseline. The invasive arm was also found to have improved 
QOL with the general health and physical functroning measures of the SF-36 showng a 
trend towards improved QOL (mean difference +6.7, P=O.lO, +13.2, P=O.lO, respec- 
tively). The SAQ angina1 stability and angina1 frequency measures showed a significant 
